Drug intelligence / Profile preview

MDM02

Development stage: Preclinical
Lead developer: Shenzhen Xbiome Biotechnology
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics

Overview

MDM02 is a preclinical-stage microbiome-derived therapeutic candidate being developed by Shenzhen Xbiome Biotech for the treatment of solid tumors. It belongs to a class of therapies known as microbe-derived molecules (MDMs), which are specific bioactive components isolated from the microbiome rather than live bacterial cells. Discovered using Xbiome's AI-driven computational platform, MDM02 is designed to exert anti-tumor or immune-modulatory effects within the tumor microenvironment. Unlike live biotherapeutic products (LBPs) that utilize formulated bacteria, MDM02 focuses on the specific molecular drivers of microbial therapeutic efficacy to achieve targeted oncological outcomes.

Beyond the preview

Go deeper on MDM02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDM02.

Explore the full profile